BFC Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$218K Sell
288
-61
-17% -$46.1K 0.01% 897
2026
Q2
$218K Buy
349
+30
+9% +$20.4K 0.01% 902
2026
Q1
$247K Sell
319
-36
-10% -$27.6K 0.01% 797
2025
Q4
$274K Buy
355
+44
+14% +$29.9K 0.01% 750
2025
Q3
$175K Buy
311
+61
+24% +$34.5K 0.01% 727
2025
Q2
$132K Buy
250
+40
+19% +$22.3K 0.01% 776
2025
Q1
$133K Buy
210
+16
+8% +$11K 0.01% 759
2024
Q4
$138K Sell
194
-153
-44% -$128K 0.01% 747
2024
Q3
$365K Buy
+347
New +$386K 0.03% 411

Other funds holding REGN

BFC Planning's REGN Position: Q3 2026 in Review

BFC Planning reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q3 2026, selling an estimated $46.1K and leaving 288 shares worth $218K. The position accounts for 0.01% of the portfolio, ranked #897.

BFC Planning first reported a position in REGN in Q3 2024 and has held it in 9 quarters since. The position peaked at $365K in Q3 2024. 1,229 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • BFC Planning held 288 shares of Regeneron Pharmaceuticals worth $218K as of Q3 2026.
  • BFC Planning sold 61 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $46.1K.
  • Regeneron Pharmaceuticals made up 0.01% of BFC Planning's portfolio in Q3 2026, its #897 holding.
  • BFC Planning first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Regeneron Pharmaceuticals position peaked at $365K in Q3 2024.
  • 1,229 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.